Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche to acquire Telavant for $7.1b.

<< Previous

Bullboard Posts

Next >>

Comment by 13X2413on Oct 23, 2023 9:44am

164 Views

Post# 35696013

RE:Roche to acquire Telavant for $7.1b.

Oncy's deal? Apparently todays news wasn't highly thought of. Why would there be interest from anybody if everything they release knocks the share price further down.

To me, it looks like ONC doesn't have much to offer. Price action=public sentiment.

<< Previous

Bullboard Posts

Next >>

Critical materials crisis: Diversifying away from China’s monopoly